Reproducing human diabetic nephropathy in a novel obesity-driven animal model

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Diabetic nephropathy is a major cause of kidney failure globally.
• Current preclinical models inadequately replicate human disease complexity and progression.
• A non-genotypic type 2 diabetes rat model using Tacrolimus was previously established.

Purpose of the Study:

• To investigate the onset and progression of diabetic nephropathy in the established Tacrolimus-induced type 2 diabetes rat model.
• To evaluate the model's capacity to replicate human diabetic nephropathy pathophysiology.
• To assess the utility of this model for studying chronic kidney disease and therapeutic strategies.

Main Methods:

• Obese Sprague Dawley rats received chronic low-dose Tacrolimus to induce type 2 diabetes.
• Glomerular filtration rate (GFR) assessed via iohexol-DBS plasma clearance.
• Albuminuria and proteinuria measured through 24-hour urine collections.
• Kidney histology, weight, and cortical pro-inflammatory marker expression analyzed at study endpoint.
• Tacrolimus blood levels monitored monthly.

Main Results:

• Diabetic rats exhibited initial glomerular hyperfiltration followed by a late-stage GFR decline.
• A trend toward increased proteinuria was observed.
• Histological findings included mesangial expansion, increased Focal Segmental Glomerulosclerosis, glomerular hypertrophy, increased kidney weight, tubular hypertrophy, fibrosis, and elevated pro-inflammatory markers.
• The model successfully reproduced early and advanced pathological features of human diabetic nephropathy.

Conclusions:

• The Tacrolimus-induced type 2 diabetes rat model effectively replicates key aspects of human diabetic nephropathy.
• This model serves as a valuable tool for investigating the chronic pathophysiology of diabetic kidney disease.
• It provides a platform for evaluating novel therapeutic interventions for diabetic nephropathy.